Sarepta Therapeutics/$SRPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,372
ISIN
US8036071004
Website
SRPT Metrics
BasicAdvanced
$1.7B
-
-$2.59
0.84
-
Price and volume
Market cap
$1.7B
Beta
0.84
52-week high
$162.95
52-week low
$16.97
Average daily volume
6.3M
Financial strength
Current ratio
4.017
Quick ratio
2.06
Long term debt to equity
117.592
Total debt to equity
118.727
Interest coverage (TTM)
-5.12%
Profitability
EBITDA (TTM)
-78.252
Gross margin (TTM)
20.14%
Net profit margin (TTM)
-11.12%
Operating margin (TTM)
-5.25%
Effective tax rate (TTM)
-51.28%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
-2.19%
Return on equity (TTM)
-23.61%
Valuation
Price to revenue (TTM)
0.735
Price to book
1.47
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-2.353
Free cash flow yield (TTM)
-42.50%
Free cash flow per share (TTM)
-727.24%
Growth
Revenue change (TTM)
59.15%
Earnings per share change (TTM)
-1,538.31%
3-year revenue growth (CAGR)
42.87%
10-year revenue growth (CAGR)
89.86%
3-year earnings per share growth (CAGR)
-15.45%
10-year earnings per share growth (CAGR)
-4.57%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Bulls say / Bears say
Sarepta Therapeutics has entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, potentially expanding its pipeline and revenue streams. (stocktitan.net)
The company reported a 25% increase in revenue for the first nine months of 2023 compared to the same period last year, indicating strong financial growth. (fool.com)
Sarepta's gene therapy, Elevidys, has been approved under the accelerated approval pathway for treating Duchenne muscular dystrophy in 4-5 year olds, marking a significant milestone in its product offerings. (wikipedia.org)
The FDA has delayed its decision on Sarepta's gene therapy SRP-9001, pushing the Prescription Drug User Fee Act (PDUFA) date from May 29 to June 22, 2023, causing uncertainty about the approval timeline. (fool.com)
Sarepta's Phase 3 EMBARK study for Elevidys failed to meet its primary endpoint, leading to a significant stock price decline and raising concerns about the therapy's efficacy. (fool.com)
The FDA's request for an advisory committee to further investigate Sarepta's DMD treatment has introduced additional regulatory hurdles, potentially delaying product approval and market entry. (entrepreneur.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action Lawsuit
GlobeNewsWire·7 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
GlobeNewsWire·2 days ago
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $1.7B as of June 30, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of June 30, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.